Zacks Investment Research upgraded shares of Quintiles Transitional Holdings Inc. (NYSE:Q) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning. They currently have $107.00 target price on the medical research company’s stock.
According to Zacks, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina. “
Several other research analysts have also recently weighed in on the company. Citigroup Inc. reiterated a neutral rating and set a $96.00 price target (up from $87.00) on shares of Quintiles Transitional Holdings in a research report on Wednesday, June 28th. Robert W. Baird upgraded Quintiles Transitional Holdings from an underperform rating to a neutral rating and lifted their price target for the company from $76.00 to $93.00 in a research report on Friday, July 7th. Barclays PLC reiterated an overweight rating and set a $98.00 price target (up from $90.00) on shares of Quintiles Transitional Holdings in a research report on Monday, July 17th. Argus lifted their price target on Quintiles Transitional Holdings from $98.00 to $104.00 and gave the company a buy rating in a research report on Monday, September 18th. Finally, Royal Bank Of Canada initiated coverage on Quintiles Transitional Holdings in a research report on Tuesday, September 19th. They set an outperform rating and a $116.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Quintiles Transitional Holdings has a consensus rating of Buy and an average price target of $93.61.
Shares of Quintiles Transitional Holdings (Q) traded up 0.71% during mid-day trading on Wednesday, hitting $98.45. 1,063,036 shares of the stock were exchanged. Quintiles Transitional Holdings has a 12 month low of $70.10 and a 12 month high of $99.95. The stock’s 50 day moving average is $95.69 and its 200 day moving average is $88.65. The firm has a market cap of $21.32 billion, a P/E ratio of 285.36 and a beta of 0.62.
Quintiles Transitional Holdings (NYSE:Q) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.04. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. The firm had revenue of $1.97 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same period last year, the business posted $0.93 earnings per share. The company’s revenue for the quarter was up 68.7% compared to the same quarter last year. Analysts expect that Quintiles Transitional Holdings will post $4.58 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Quintiles Transitional Holdings Inc. (Q) Upgraded by Zacks Investment Research to “Buy”” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thestockobserver.com/2017/10/12/quintiles-transitional-holdings-inc-q-upgraded-by-zacks-investment-research-to-buy.html.
In other Quintiles Transitional Holdings news, insider Kevin C. Knightly sold 19,339 shares of Quintiles Transitional Holdings stock in a transaction on Friday, August 25th. The stock was sold at an average price of $99.51, for a total value of $1,924,423.89. Following the sale, the insider now owns 40,650 shares in the company, valued at $4,045,081.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ari Bousbib sold 46,080 shares of Quintiles Transitional Holdings stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $94.91, for a total value of $4,373,452.80. Following the completion of the sale, the insider now owns 1,036,839 shares in the company, valued at approximately $98,406,389.49. The disclosure for this sale can be found here. Insiders sold 14,198,382 shares of company stock worth $1,361,834,375 in the last 90 days. Company insiders own 6.40% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Quintiles Transitional Holdings by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 12,789,723 shares of the medical research company’s stock worth $1,144,680,000 after purchasing an additional 280,893 shares during the period. BlackRock Inc. increased its holdings in Quintiles Transitional Holdings by 4,217.1% during the 1st quarter. BlackRock Inc. now owns 7,098,723 shares of the medical research company’s stock worth $571,660,000 after purchasing an additional 6,934,290 shares during the period. KBC Group NV increased its holdings in Quintiles Transitional Holdings by 53.3% during the 2nd quarter. KBC Group NV now owns 18,959 shares of the medical research company’s stock worth $1,697,000 after purchasing an additional 6,591 shares during the period. Key Square Capital Management LLC purchased a new stake in Quintiles Transitional Holdings during the 2nd quarter worth about $2,738,000. Finally, AXA increased its holdings in Quintiles Transitional Holdings by 85.4% during the 2nd quarter. AXA now owns 251,830 shares of the medical research company’s stock worth $22,539,000 after purchasing an additional 115,993 shares during the period. Hedge funds and other institutional investors own 93.21% of the company’s stock.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.